References
- Rasche L, Weinhold N, Morgan GJ, et al. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017;55:190–199.
- Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854–858.
- Rawstron AC, Davies FE, Owen RG, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol. 1998;100:176–183.
- Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658–2663.
- Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.
- Gonzalez-Calle V, Cerda S, Labrador J, et al. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017;102:922–931.
- Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115–1123.
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
- Tovar N, de Larrea CF, Arostegui JI, et al. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica. 2013;98:1142–1146.
- Kastritis E, Zagouri F, Symeonidis A, et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014;28:2075–2079.
- Ludwig H, Milosavljevic D, Berlanga O, et al. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. Am J Hematol. 2016;91:295–301.
- Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer. 1990;26:363–371.
- Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid. 2017;24:44–45.
- Muchtar E, Dispenzieri A, Kumar SK, et al. Immuno-paresis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid. 2017;24:40–41.
- Holmberg LA, Becker PS, Bensinger W. Results from two consecutive studies of consolidation therapy after autologous transplant for multiple myeloma: thalidomide, dexamethasone, and clarithromycin or lenalidomide, dexamethasone, and clarithromycin. Acta Haematol. 2017;137:123–131.
- Sengsayadeth S, Malard F, Savani BN, et al. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017;7:e545.
- Vo MC, Anh-NguyenThi T, Lee HJ, et al. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol. 2017;46:48–55.